



## Review Article

# Mind the Gaps: Ontogeny of Human Brain P-gp and Its Impact on Drug Toxicity

Jean-Marie Nicolas<sup>1,3</sup>  and Elizabeth C. M. de Lange<sup>2</sup>

Received 5 March 2019; accepted 10 May 2019; published online 28 May 2019

**Abstract.** Available data on human brain P-glycoprotein ontogeny during infancy and childhood are limited. This review discusses the current body of data relating to maturation of human brain P-glycoprotein including transporter expression levels in post-mortem human brain samples, *in vivo* transporter activity using probe substrates, surrogate marker endpoints, and extrapolations from animal models. Overall, the data tend to confirm that human brain P-glycoprotein activity keeps developing after birth, although with a developmental time frame that remains unclear. This knowledge gap is a concern given the critical role of brain P-glycoprotein in drug safety and efficacy, and the vulnerable nature of the pediatric population. Future research could include the measurement of brain P-glycoprotein activity across age groups using positron emission tomography or central pharmacodynamic responses. For now, caution is advised when extrapolating adult data to children aged younger than 2 years for drugs with P-glycoprotein-dependent central nervous system activity.

**KEY WORDS:** blood-brain barrier; brain; ontogeny; pediatric; P-glycoprotein.

## INTRODUCTION

Cellular plasma membrane transporters are expressed in various tissues and ensure the uptake of endogenous and exogenous substances into cells, as well as their efflux. Hundreds of transporters have been identified, with about 20 being recognized as playing a role in drug absorption, distribution, and excretion (1). The multi-drug efflux pump P-glycoprotein (P-gp; also termed multi-drug resistance protein 1 [MDR1]; encoded by the *ABCB1* gene) belongs to the ATP-binding cassette (ABC) superfamily. Since its discovery more than 40 years ago (2), the function, localization, and regulation of P-gp have been extensively studied. P-gp is expressed throughout the body, typically at the apical surface of polarized cells from the liver and the kidneys, where it contributes to drug elimination. At physiological barriers such as the intestine, blood-brain barrier (BBB), and others (e.g., placenta and testis), P-gp is expressed at the luminal surface of cells, where it effluxes substrates and restricts their absorption or distribution into tissues.

P-gp is remarkable in its ability to transport a wide range of substances owing to its multiple substrate-binding sites. Changes in P-gp function have a profound effect on the

pharmacokinetics, tissue distribution, efficacy, and toxicity of drugs that are substrates for this transporter. As an example, the over-the-counter anti-diarrheal drug loperamide is a potent synthetic  $\mu$ -opioid agonist which, under normal circumstances, is devoid of central opioid side effects as a result of P-gp-mediated efflux and thus has limited brain distribution (3). However, concomitant administration of loperamide with strong P-gp inhibitors (e.g., quinidine and omeprazole) may lead to respiratory depression (3) and euphoria with abuse potential (4). Secondly, the etexilate prodrug of the anti-coagulant dabigatran shows poor oral absorption because of intestinal P-gp efflux (4). Co-administration with P-gp inhibitors has been reported to increase dabigatran exposure and therefore risk of severe hemorrhage (5).

Although less studied, the activity of the various drug transporters can change during growth and development, with potential impact on drug pharmacokinetics, pharmacodynamics, and safety in children (6–8). The International Transporter Consortium (ITC) recently issued a white paper about the ontogeny of drug transporters, reviewing the limited existing data and their clinical relevance for pediatrics, and making some recommendations (9). Notably, only intestinal-, hepatic-, and renal-transporter activities were discussed, without any mention of brain tissue. This underscores the paucity of information about brain P-gp ontogeny, which itself probably reflects the numerous technical and ethical challenges impeding investigations. However, this knowledge gap contrasts with the pressing need to better understand changes in drug kinetics during childhood, in order to determine appropriate pediatric dosing (10). Indeed, most of the drugs prescribed to children are off-

<sup>1</sup> Quantitative Pharmacology DMPK Department, UCB BioPharma, Chemin du Foriest, 1420, Braine L'Alleud, Belgium.

<sup>2</sup> Research Division of Systems Biomedicine and Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands.

<sup>3</sup> To whom correspondence should be addressed. (e-mail: Jean-Marie.Nicolas@ucb.com)

label or unlicensed, with few (if any) clinical data available, and with rudimentary dose adjustment (11), which leaves this vulnerable population at risk of adverse safety reactions and efficacy failures.

This review discusses the available literature relating to brain P-gp ontogeny in humans and its relevance to drug safety in children. Immunohistochemistry data obtained in post-mortem human brain samples are reviewed, as well as information derived from alternate readouts such as CSF sampling, brain PET imaging, central nervous system (CNS) pharmacodynamic effects, and animal studies.

### Immunohistochemical Investigations Using Post-mortem Human Brain Samples

A pioneering study performed in the late 1990s demonstrated P-gp expression in brain microvessels as early as 8 weeks of gestation (12). A subsequent study showed a gradual increase in brain microvessel P-gp expression with gestational age (13). The developmental pattern showed regional differences with an earlier P-gp expression in posterior forebrain when compared to cerebral cortex. Importantly, P-gp expression levels measured in post-mortem samples from term newborns were lower than those in adults, leaving open the question of post-natal maturation of P-gp.

This question was addressed in a work recently published by Lam *et al.* that examined samples from gestational age 20–26 weeks to post-natal age 3–6 months and compared them to adults (14) (Table I). P-gp protein levels were measured by immunohistochemistry in formalin-fixed, paraffin-embedded, post-mortem brain samples. The authors reported that P-gp expression was limited at birth and increased to adult levels at post-natal age 3–6 months. The authors acknowledged several limitations in their study. Post-mortem interval, method of tissue fixation, and donor P-gp genotype were unknown, which all may affect P-gp level determination. Tissue autofluorescence (e.g., involving lipofuscin) was discussed as another potential confounding variable in the P-gp immunoassay, as well as the fact that only cortex samples were examined. These concerns are not unique to this study: previous immunohistochemical studies measuring P-gp in tissues have produced conflicting results that were ascribed to similar methodological challenges (23,24). One could also add that the pediatric samples in Lam's report were compared with a rather old adult population (mean age of 53.6 years), which may complicate data interpretation as brain P-gp levels are known to decline with aging (25,26). Finally, caution is warranted when interpreting P-gp protein expression data, which may not directly correlate with transporter activity (27–31). Discrepancies would not be unexpected as P-gp activity is influenced by numerous factors beyond the expression of the protein itself, e.g., transporter conformation (31), membrane lipid environment (29), and extracellular pH (32).

However, it should be emphasized that the availability of quality human pediatric tissues is scarce and does not allow for P-gp investigations with larger sample sizes and better-controlled conditions (9). Despite all the above-mentioned limitations, Lam's study is cited by many review articles stating that human brain P-gp is fully mature at 3–6 months of age (7,35–39).

### In Vivo Functional Activity of P-gp in Human BBB

As discussed above, P-gp expression levels in post-mortem or surgical samples may not be predictive of functional activity *in vivo*. However, assessing brain P-gp activity in human subjects is challenging, particularly in young children. An *in vivo* probe substrate for brain P-gp should combine selectivity towards the transporter, efficient efflux, low metabolism, high tolerability, and sensitive bioanalytics. Performing pharmacokinetic studies in pediatrics represents an additional challenge given the numerous technical, ethical, and regulatory hurdles. A recent review of 1081 registered clinical trials in children revealed that only 24% incorporated pharmacokinetic measurements and that 74% were conducted in children aged over 2 years (40), while changes in drug pharmacokinetics tend to predominate in younger children. From an ethical and regulatory perspective, studies are not generally acceptable in healthy children, and drugs investigated in ill children should either provide a direct benefit to the subjects or be used at a dose where risks are minimal (41).

The methods for estimating brain pharmacokinetics in the clinic are very few and mostly restricted to cerebrospinal fluid sampling and positron emission tomography.

#### Cerebrospinal Fluid Sampling

Although the blood-CSF barrier differs from the BBB, especially with respect to active transporters such as P-gp (13,42–45), drug concentration in lumbar, cisternal, and ventricular CSF may provide an indirect indication of brain levels. CSF sampling has been widely used in adolescents and adults to determine human brain P-gp activity towards centrally acting drugs, and its changes in disease states or resulting from P-gp/ABCB1 polymorphism (46–49). However, data in children are scarce and CSF sampling has never been used to specifically investigate the post-natal maturation of brain P-gp activity.

Vincristine (VCR) is a plant alkaloid widely used as an intravenous infusion for the treatment of childhood and adult malignancies. A study in 17 pediatric patients (aged 2.5–14 years) measured paired VCR levels in plasma and CSF after intravenous dosing (15) (Table I). No measurable VCR was detected in CSF samples, with CSF/plasma ratios < 5% irrespective of patient age. CSF-to-free plasma-level ratios were estimated to be < 0.16 (detection limit 0.1 ng/mL, VCR plasma protein binding 71% (50)). Since VCR is a P-gp substrate (51), the data above could be interpreted as brain P-gp being fully mature from 2.5 years onwards. These findings should be taken with caution as the study did not investigate younger ages. Also, the data were from patients treated for acute lymphoblastic leukemia or non-Hodgkin lymphoma, disease states often associated with overexpression of P-gp (52,53). Finally, VCR also interacts with other transporters such as multi-drug resistance-associated proteins (MRPs) (54,55) and organic anion transporting polypeptides (OATPs) (56).

Amphotericin B (AmB) is a potent anti-fungal known for showing poor brain penetration and extensive P-gp-mediated efflux (57). Although several studies reported undetectable AmB levels in CSF across various age groups

**Table I.** Effect of Age on Various Potential Readouts of Human Brain P-gp Activity

Species	Experimental approach	N	Age <sup>a</sup>	Conclusion
Human	Protein expression of brain P-gp by immunohistochemistry of post-mortem human brain cortex samples (13)	9	22–26 weeks <sup>b</sup>	Positive P-gp immunostaining of microvessel endothelial cells from 22 to 26 weeks gestation (brainstem, hindbrain, and thalamus) and from 27 to 32 weeks gestation (other regions of the forebrain). Lower signal at birth than in adults.
		10	27–32 weeks <sup>b</sup>	
		9	33–42 weeks <sup>b</sup>	
	3	adults		
	Protein expression of brain P-gp by immunohistochemistry of post-mortem human brain cortex samples (14)	8	0–3 months	Brain P-gp expression mature at 3–6 months of age
		7	3–6 months	
	VCR concentration in CSF samples (15)	8	54 ± 7 years	Brain P-gp function mature at ≤ 2.5 years
	Meta-analysis of CNS toxicity with loperamide (16)	17	2.5–14 years	
	CNS toxicity with CsA (17)	1788	1 month–12 years	Increased frequency of CNS side effects with loperamide in children aged < 3 years vs older children or placebo
		146	5 months–18 years	Regression analysis identified age < 6 years as a risk factor for CNS side effects with CsA
Rat <sup>c</sup>	Brain distribution of oseltamivir, brain P-gp protein and mRNA levels (18)	na	3–42 days	Brain P-gp expression and function mature at 21 days
		na	7–44 days	Brain P-gp function mature at 21–24 days
	Brain PET imaging with [ <sup>11</sup> C]-oseltamivir (19)	na	14–56 days	Brain P-gp expression and function mature at 21 days
Monkey <sup>c</sup>	Brain PET imaging with [ <sup>11</sup> C]-verapamil (21)	na	9 months–7 years	Brain P-gp function not fully mature in infant (9 months) or adolescent (24–27 months) monkeys
	Protein expression of brain P-gp levels by LC-MS/MS (22)	na	20-week fetus–50 years	Brain P-gp expression mature at 3–6 months

CNS central nervous system, CsA cyclosporine A, CSF cerebrospinal fluid, LC-MS/MS liquid chromatography-tandem mass spectrometry, mRNA messenger ribonucleic acid, na not applicable, PET positron emission tomography, P-gp P-glycoprotein, VCR vincristine

<sup>a</sup> Unless otherwise stated, postnatal age

<sup>b</sup> Gestational age

<sup>c</sup> 21 days of rat age reported to correspond to around 1–2 years of human age; 9 months of Rhesus monkey age reported to correspond to around 4 years of human age (33,34)

(58–60), the methods used were not sensitive enough to quantify the low concentrations expected due to high plasma protein binding of AmB. A more recent study in subjects approximately 8 years old used a highly sensitive AmB assay and established that CSF concentrations corresponded to 0.13% of serum levels (61); this translates into a CSF-to-free serum-level ratio of approximately 0.26 (assuming 99.5% plasma protein binding (62)), confirming restricted BBB penetration. AmB CSF concentrations reported in pre-term neonates are surprisingly high, i.e., up to 40–90% of the concentration measured in paired serum samples (63). It could be hypothesized that the higher CSF levels in neonates relate to immature brain P-gp. However, as for VCR, these data should be interpreted with caution since the role of P-gp in AmB distribution is still debated (64,65) and age-related changes in plasma protein binding may have also contributed to the higher AmB CSF concentrations in neonates (66). Moreover, it should be realized that CSF concentrations do not directly reflect brain extracellular fluid (ECF) concentrations. The relationship between brain ECF and CSF is drug dependent, system dependent, and time dependent, and it is the brain ECF concentrations that are needed to understand P-gp activity at the level of the BBB (45).

#### *Positron Emission Tomography*

PET imaging has been proposed as an alternative to CSF sampling to investigate drug distribution across the BBB. PET has the advantages of being non-invasive and allowing regional distribution studies (67). On the other hand, PET remains expensive and technically challenging. In addition, the PET signal is not easy to interpret since it shows the total concentration in the tissue of interest; it does not allow discrimination between the intact tracer and its labeled metabolites, nor between free and bound material. The PET signal also does not differentiate between the intracellular, extracellular, and intravascular compartments (68). PET has been applied to measure brain P-gp functional activity in animals and humans using [<sup>11</sup>C]-labeled probe markers, e.g., [<sup>11</sup>C]-verapamil and [<sup>11</sup>C]-desmethyl-loperamide. So far, human PET studies have been restricted to adults, measuring brain P-gp activity in disease states and/or following co-administration with P-gp inhibitors (68). There are no reports of PET studies investigating brain P-gp maturation in children.

#### **P-gp Activity in Peripheral Tissues as a Surrogate Marker of Activity in the Brain**

Given the difficulties in quantifying *in vivo* brain P-gp functional activity in young children, a surrogate marker with easier access would be useful. P-gp is present in various tissues, particularly blood cells that are easy to collect. However, available literature suggests that P-gp functional activity varies across tissues, making blood cell assays unlikely to quantitatively predict the BBB situation. *In vivo*, brain P-gp is more resistant to inhibition than P-gp in blood lymphocytes (69–71). Similarly, *in vitro* data showed that circulating lymphocytes and brain endothelial cells respond differently to P-gp inducers, suggesting different mechanisms of transporter regulation (72). It has also been suggested that the location of P-gp within the cell membrane, its lipid microenvironment, and its expression level might differ between blood

lymphocytes and brain endothelial cells, which could account for the observed differences in activity (69). In circulating T lymphocytes and NK cells, P-gp activity is maximal at birth and gradually decreases to adult levels at 6 months of age (73,74), suggesting that blood lymphocytes and brain have an opposite time frame with respect to P-gp maturation.

The organ-specific pattern of P-gp development has been already discussed for other peripheral tissues (7,38). Based on protein expression data, hepatic P-gp reaches adult levels at 1 year of age (75), duodenal P-gp appears fully mature from birth (76,77), while placenta P-gp decreases with advancing gestation (78). The mechanisms and physiological reasons for these tissue differences remain unclear. Overall, it is unlikely that P-gp maturation in peripheral tissues or blood cells will be informative for the situation at the BBB level.

#### **CNS Pharmacodynamic Response as a Surrogate Marker of Brain P-gp Activity**

Under certain circumstances, central effects of P-gp substrates on the brain may be considered as a potential surrogate for measuring the transporter activity at the BBB. This necessitates a drug with sizable P-gp-mediated efflux and easily measurable CNS pharmacological or toxicological response.

When taken as advised, loperamide does not elicit central opioid activity because of restricted brain penetration, a consequence of P-gp-mediated efflux (79). However, cases of neurological side effects have been reported in young children given loperamide (80–82). A large meta-analysis of 13 selected, randomized, controlled trials in children (total of 1788 children aged 1 month to 12 years) (16) (Table I) confirmed that loperamide is mostly efficacious and safe. However, serious adverse events were reported among loperamide-treated children aged <3 years, compared with none in older children or those allocated to placebo. It has been suggested that decreased brain P-gp function in children might account for their increased vulnerability to loperamide CNS side effects (83).

Buprenorphine is a partial agonist of  $\mu$ -opioid receptors used in adults for treatment of pain and narcotic addiction. It is also a valuable treatment option for neonatal abstinence syndrome, a condition affecting newborns that were exposed to opioids in utero (84). Norbuprenorphine, the major active metabolite, is a substrate of P-gp, which limits its brain distribution and partly masks its potential to provoke CNS depression (85). Buprenorphine has been rarely linked to overdose in adults and children. However, children under 2–3 years do not respond well to buprenorphine overdosage showing CNS toxicity such as respiratory and CNS depression, altered mental status and miosis (84,86–88). In theory, immature P-gp in children could allow higher brain exposure to norbuprenorphine (83,87). Other mechanisms could also account for the observed findings, for example a “ceiling” pharmacodynamics effect might limit respiration depression in adults but not in very young children (86).

Cyclosporin A (CsA) is a potent, amino acid-containing immunosuppressant. It is a P-gp substrate (89) that usually shows restricted distribution to the brain (90). However, severe neurotoxicity is a recognized complication of CsA

that can manifest as seizures, acute encephalopathy, coma, cerebral hemorrhage, and cortical blindness. It is not directly linked to CsA dose or plasma exposure (91); the exact underlying mechanisms are poorly understood and likely to be multi-factorial (92). Many risk factors have been identified, including co-administration with anti-cancer drugs and glucocorticoids, hypertension, hepatic and renal dysfunction, cerebral ischemia or hemorrhage, and low serum cholesterol (93,94). A retrospective study in 146 children (from 0.4 to 18 years of age) demonstrated that age is another risk factor for CsA neurotoxicity (17). Age < 6 years was found to be significantly associated with CsA encephalopathy (Table I), possibly because of immature brain P-gp.

As described earlier, VCR is a plant alkaloid widely used as an intravenous infusion for the treatment of childhood and adult malignancies such as lymphoma, leukemia, and rhabdomyosarcoma. Severe and often fatal CNS toxicity has been reported following accidental intrathecal administration of VCR (95). Under normal circumstances, central side effects are rare since the drug does not distribute into the brain (15,96) as a consequence of its extensive efflux by P-gp and MRPs (55). Disruption of the BBB, for example due to brain tumor (55), osmotic opening (97), or impaired brain P-gp activity (98,99), potentially increases distribution of VCR to the brain and increases its central toxicity. Presumably, immature brain P-gp in young children could also translate into increased VCR central side effects. However, to our knowledge, there are no published reports suggesting a higher incidence of VCR-induced central side effects in young children *versus* older age groups.

Most of the above examples tend to confirm post-natal development of brain P-gp activity. However, these reports do not allow a precise clarification of the time frame of the transporter maturation, as some important variables were not controlled, e.g., P-gp genotype, environmental exposure, potential age-related changes in systemic drug levels, or in the expression of the target(s) driving the CNS response (such as for dopamine neurotransmission (100), GABA<sub>A</sub> (101,102), or SV2A' (103)). Measuring CNS pharmacodynamics response as a surrogate marker of P-gp activity remains a viable future option for controlled prospective studies.

### Extrapolations from Animal Models to Humans

Measuring protein expression levels and/or functional activity of BBB transporters in laboratory animals at various post-natal ages might potentially provide an indication of the human situation (9,104,105).

Age-related changes in brain disposition of various P-gp probe substrates have been thoroughly investigated in rodents. After intravenous infusion to male Wistar rats, the brain-to-plasma concentration ratio of the P-gp substrate oseltamivir was highest in 3-day-old pups and decreased to adult levels from 21 days onwards (Table I) (18). These data were confirmed in a subsequent PET imaging study with [<sup>11</sup>C]-oseltamivir (19) and in a tissue distribution study using digoxin, another P-gp substrate (20). The above age-related changes in brain P-gp function broadly parallel the changes in mRNA (18,20,106,107) and protein (108–110) expression in brain microvessels, with adult levels being reached at postnatal weeks 3–4. In rats, the expression profile of P-gp protein appears to be comparable in the capillaries of

cerebral cortex, hippocampus, and cerebellum (108). The developmental pattern of brain P-gp in mice is similar than in rat. A report investigating the brain disposition of the P-gp substrate CsA in mice demonstrated around 4-fold higher brain P-gp activity in adults compared with 1-day-old animals, and mature levels were achieved at around 19 days of age (111). Similarly, P-gp expression in mouse brain was found to be limited during embryogenesis and to increase with postnatal maturation. By day 21, brain P-gp protein expression approximates adult levels (112).

The numerous and well-aligned datasets in mice and rat contrast with very few and conflicting reports in non-human primates. In a comprehensive PET study in Rhesus monkeys, the brain-uptake clearance of R-[<sup>11</sup>C]-verapamil, a parameter that is inversely proportional to P-gp activity at the BBB, was significantly higher in infant animals (9 months) compared with adolescents (24–27 months) or adults (5.6–6.6 years):  $0.14 \pm 0.04$ ,  $0.09 \pm 0.02$ , and  $0.06 \pm 0.01$  mL/min/g, respectively (mean  $\pm$  standard deviation of five animals per group) (21) (Table I). This finding suggests a rather delayed maturation of brain P-gp, which contrasts with a concurrent study reported in cynomolgus monkeys (22). In this later study, brain P-gp was claimed to be mature at birth since similar P-gp protein levels were measured in 1-day-, 16-month-, and 4-year-old animals. However, these data should be interpreted with caution given the small sampling size (i.e., one animal per group) and potential disconnect between protein expression and functional activity.

Overall, from the above data, brain P-gp activity appears to be mature in rodents from ca. 3-week post-natal age and in Rhesus monkeys aged >9 months. Translating these data to humans should consider potential species differences in organ and function maturation. Using a “neuroinformatic” approach combining various neurodevelopmental endpoints (33), 3 weeks of rat age would correspond to 1–2 years of human age, with 9 months in Rhesus monkey age corresponding to approximately 4 years in humans. Broadly similar schedules can be derived from the popular age-comparative categories described by Buelke-Sam, which are based on overall CNS and reproductive development (113). One major weakness of this approach is that it assumes that brain P-gp development parallels other CNS endpoints such as neurogenesis, myelination, sensorimotor function, and brain growth. Such assumptions might be flawed, as illustrated by intestinal P-gp. Indeed, human intestinal P-gp is fully mature at birth (76,114) while other intestinal functions, such as duodenal CYP3A4 activity, intestinal cell morphology, and Peyer’s patch development, show delayed maturation (115–117). Translating brain P-gp maturation data from animals to humans is made even more complex by species differences in BBB transporter expression and activity, especially between rodents and primates (118–120). Overall, although strongly indicating maturation of BBB P-gp after birth, the actual animal data are somewhat conflicting and difficult to extrapolate to humans, especially in refining the maturation time frame of the transporter.

### Physiologically Based Pharmacokinetic Modeling of CNS

PBPK modeling is increasingly used to investigate drug pharmacokinetics in children (121–123). PBPK is a

mechanism-based modeling approach where all drug metabolism and pharmacokinetic processes and their interconnections are described mathematically. A broad range of input data (*in silico*, *in vitro*, pre-clinical and clinical data) can be incorporated to parameterize the PBPK model for both system-specific (e.g., anatomy, physiology, flow rates, tissue volume and composition, or metabolizing enzyme activity) and drug-specific (e.g., solubility, permeability, metabolic clearance, or fraction bound to plasma proteins) parameters. Typically, an adult PBPK model is first built, then refined and verified against measured clinical data. Later, system parameters can be adjusted to account for maturational changes in pharmacokinetic processes, and the model can be used to predict pharmacokinetics in children (121).

So far, pediatric PBPK modeling has primarily been applied *a posteriori* using data for well-known reference drugs, in order to explore the maturation of renal and metabolic clearance processes (124–129). *A priori* pediatric PBPK studies for guiding dose selection and trial design are far fewer (130–132). The prospective use of pediatric PBPK models is hindered by limited understanding of age-related changes in some pharmacokinetic mechanisms. The developmental patterns of processes involved in oral drug absorption remain particularly poorly characterized (114,133). The information gap around the ontogeny of P-gp activity is another critical limitation, especially when the PBPK model is intended to predict drug concentrations in the brain and associated CNS therapeutic or toxic activities. To our knowledge, there are no published PBPK reports investigating the CNS distribution of P-gp substrates in pediatric vs adult populations. Predicting the distribution of P-gp substrates across adult BBB, i.e., ignoring age-related changes, remains a challenging task (134–137). Recently, Yamamoto *et al.* reported a generic CNS PBPK model to predict the concentration-time profile of drugs in various compartments of adult rat (138) and human (139) brain. The model was validated against multiple drugs with varying physicochemical properties and active transport activities. Moreover, this model was instrumental in predicting morphine brain concentrations in children with traumatic brain injury (140). Hopefully, as knowledge of ontogeny of brain P-gp improves, it will become possible to extend PBPK models to predict brain disposition in children.

## CONCLUSIONS

Reliable data on the timing of postnatal maturation of human brain P-gp activity are scarce. Our review of data from a variety of sources tends to confirm that post-natal changes in human brain P-gp activity occur, but does not allow a precise determination of the time schedule (Table I). Depending on the data considered, maturation could be achieved either at term birth or not until several years of age. Unfortunately, measuring brain P-gp functional activity in pediatric subjects is associated with considerable technical, ethical, and regulatory challenges. In the future, prospective studies using PET imaging or assessment of CNS pharmacodynamic responses may provide more robust insights into the normal human brain P-gp maturation pattern. Undoubtedly, a better understanding of the mechanisms underlying the

maturation of P-gp in brain microvessels would also contribute filling the knowledge gaps and/or identifying other biomarkers. For instance, astrocytes have been suggested to modulate P-gp through multiple signaling pathways (e.g., TGF- $\beta$ 1, lipids) that are sensitive to developmental changes and disease effects (141–143). Once available, all these data could be used to refine the currently available human CNS PBPK model and to predict brain-drug disposition in pediatric patients. However, for now, caution is advised when extrapolating adult data to children aged younger than 2 years for drugs with P-gp-dependent CNS activity.

## ACKNOWLEDGMENTS

The authors would like to acknowledge Laura Griffin, PhD, of iMed Comms, Macclesfield, UK, an Ashfield Company, part of UDG Healthcare plc for editing assistance that was funded by UCB Pharma in accordance with Good Publications Practice (GPP3) guidelines (<http://www.ismpp.org/gpp3>).

## COMPLIANCE WITH ETHICAL STANDARDS

**Conflict of Interest** The authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

## REFERENCES

1. International Transporter C, Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, *et al.* Membrane transporters in drug development. *Nat Rev Drug Discov.* 2010;9(3):215–36.
2. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. *Biochim Biophys Acta.* 1976;455(1):152–62.
3. Sadeque AJ, Wandel C, He H, Shah S, Wood AJ. Increased drug delivery to the brain by P-glycoprotein inhibition. *Clin Pharmacol Ther.* 2000;68(3):231–7.
4. Borron SW, Watts SH, Tull J, Baeza S, Diebold S, Barrow A. Intentional misuse and abuse of Loperamide: a new look at a drug with "low abuse potential". *J Emerg Med.* 2017;53(1):73–84.
5. Walenga JM, Adiguzel C. Drug and dietary interactions of the new and emerging oral anticoagulants. *Int J Clin Pract.* 2010;64(7):956–67.
6. Elmorsi Y, Barber J, Rostami-Hodjegan A. Ontogeny of hepatic drug transporters and relevance to drugs used in pediatrics. *Drug Metab Dispos.* 2016;44(7):992–8.
7. Mooij MG, Nies AT, Knibbe CA, Schaeffeler E, Tibboel D, Schwab M, *et al.* Development of human membrane transporters: drug disposition and pharmacogenetics. *Clin Pharmacokinet.* 2016;55(5):507–24.
8. Lam J, Koren G. P-glycoprotein in the developing human brain: a review of the effects of ontogeny on the safety of opioids in neonates. *Ther Drug Monit.* 2014;36(6):699–705.
9. Brouwer KL, Aleksunes LM, Brandys B, Giacoia GP, Knipp G, Lukacova V, *et al.* Human ontogeny of drug transporters: review and recommendations of the pediatric transporter working group. *Clin Pharmacol Ther.* 2015;98(3):266–87.
10. Elzagallaai AA, Greff M, Rieder MJ. Adverse drug reactions in children: the double-edged sword of therapeutics. *Clin Pharmacol Ther.* 2017;101(6):725–35.
11. Conroy S, Choonara I, Impicciatore P, Mohn A, Arnell H, Rane A, *et al.* Survey of unlicensed and off label drug use in

- paediatric wards in European countries. European network for drug investigation in children. *BMJ*. 2000;320(7227):79–82.
12. Schumacher U, Mollgard K. The multidrug-resistance P-glycoprotein (Pgp, MDR1) is an early marker of blood-brain barrier development in the microvessels of the developing human brain. *Histochem Cell Biol*. 1997;108(2):179–82.
  13. Daood M, Tsai C, Ahdab-Barmada M, Watchko JF. ABC transporter (P-gp/ABCB1, MRP1/ABCC1, BCRP/ABCG2) expression in the developing human CNS. *Neuropediatrics*. 2008;39(4):211–8.
  14. Lam J, Baello S, Iqbal M, Kelly LE, Shannon PT, Chitayat D, *et al*. The ontogeny of P-glycoprotein in the developing human blood-brain barrier: implication for opioid toxicity in neonates. *Pediatr Res*. 2015;78(4):417–21.
  15. Kellie SJ, Barbaric D, Koopmans P, Earl J, Carr DJ, de Graaf SS. Cerebrospinal fluid concentrations of vincristine after bolus intravenous dosing: a surrogate marker of brain penetration. *Cancer*. 2002;94(6):1815–20.
  16. Li ST, Grossman DC, Cummings P. Loperamide therapy for acute diarrhea in children: systematic review and meta-analysis. *PLoS Med*. 2007;4(3):e98.
  17. Chen LW, Chen JS, Tu YF, Wang ST, Wang LW, Tsai YS, *et al*. Age-dependent vulnerability of cyclosporine-associated encephalopathy in children. *Eur J Paediatr Neurol*. 2015;19(4):464–71.
  18. Ose A, Kusuvara H, Yamatsugu K, Kanai M, Shibasaki M, Fujita T, *et al*. P-glycoprotein restricts the penetration of oseltamivir across the blood-brain barrier. *Drug Metab Dispos*. 2008;36(2):427–34.
  19. Hatori A, Yui J, Yanamoto K, Yamasaki T, Kawamura K, Takei M, *et al*. Determination of radioactivity in infant, juvenile and adult rat brains after injection of anti-influenza drug [(1)(1)C]oseltamivir using PET and autoradiography. *Neurosci Lett*. 2011;495(3):187–91.
  20. Soares RV, Do TM, Mabondzo A, Pons G, Chhun S. Ontogeny of ABC and SLC transporters in the microvessels of developing rat brain. *Fundam Clin Pharmacol*. 2016;30(2):107–16.
  21. Takashima T, Yokoyama C, Mizuma H, Yamanaka H, Wada Y, Onoe K, *et al*. Developmental changes in P-glycoprotein function in the blood-brain barrier of nonhuman primates: PET study with R-11C-verapamil and 11C-oseltamivir. *J Nucl Med*. 2011;52(6):950–7.
  22. Ito K, Uchida Y, Ohtsuki S, Aizawa S, Kawakami H, Katsukura Y, *et al*. Quantitative membrane protein expression at the blood-brain barrier of adult and younger cynomolgus monkeys. *J Pharm Sci*. 2011;100(9):3939–50.
  23. Volk H, Potschka H, Loscher W. Immunohistochemical localization of P-glycoprotein in rat brain and detection of its increased expression by seizures are sensitive to fixation and staining variables. *J Histochem Cytochem*. 2005;53(4):517–31.
  24. Toth K, Vaughan MM, Slocum HK, Arredondo MA, Takita H, Baker RM, *et al*. New immunohistochemical "sandwich" staining method for mdr1 P-glycoprotein detection with JSB-1 monoclonal antibody in formalin-fixed, paraffin-embedded human tissues. *Am J Pathol*. 1994;144(2):227–36.
  25. Bartels AL, Kortekaas R, Bart J, Willemsen AT, de Klerk OL, de Vries JJ, *et al*. Blood-brain barrier P-glycoprotein function decreases in specific brain regions with aging: a possible role in progressive neurodegeneration. *Neurobiol Aging*. 2009;30(11):1818–24.
  26. van Assema DM, Lubberink M, Boellaard R, Schuit RC, Windhorst AD, Scheltens P, *et al*. P-glycoprotein function at the blood-brain barrier: effects of age and gender. *Mol Imaging Biol*. 2012;14(6):771–6.
  27. Kosztyu P, Dolezel P, Vaclavikova R, Mlejnek P. Can the assessment of ABCB1 gene expression predict its function in vitro? *Eur J Haematol*. 2015;95(2):150–9.
  28. De Lange ECM, Vd Berg DJ, Bellanti F, Voskuyl RA, Syvanen S. P-glycoprotein protein expression versus functionality at the blood-brain barrier using immunohistochemistry, microdialysis and mathematical modeling. *Eur J Pharm Sci*. 2018;124:61–70.
  29. Bailly JD, Muller C, Jaffrezou JP, Demur C, Gassar G, Bordier C, *et al*. Lack of correlation between expression and function of P-glycoprotein in acute myeloid leukemia cell lines. *Leukemia*. 1995;9(5):799–807.
  30. Vasquez EM, Petrenko Y, Jacobssen V, Sifontis NM, Testa G, Sankary H, *et al*. An assessment of P-glycoprotein expression and activity in peripheral blood lymphocytes of transplant candidates. *Transplant Proc*. 2005;37(1):175–7.
  31. Krawczenko A, Bielawska-Pohl A, Wojtowicz K, Jura R, Paprocka M, Wojdat E, *et al*. Expression and activity of multidrug resistance proteins in mature endothelial cells and their precursors: a challenging correlation. *PLoS One*. 2017;12(2):e0172371.
  32. Thews O, Gassner B, Kelleher DK, Schwerdt G, Gekle M. Impact of extracellular acidity on the activity of P-glycoprotein and the cytotoxicity of chemotherapeutic drugs. *Neoplasia*. 2006;8(2):143–52.
  33. Clancy B, Finlay BL, Darlington RB, Anand KJ. Extrapolating brain development from experimental species to humans. *Neurotoxicology*. 2007;28(5):931–7.
  34. Buelke-Sam J. Comparative schedules of development in rats and humans: implications for developmental neurotoxicity testing. Annual meeting of the Society of Toxicology, Salt Lake City, 2003. p. Abstract no 820.
  35. Schmitt G, Parrott N, Prinssen E, Barrow P. The great barrier belief: the blood-brain barrier and considerations for juvenile toxicity studies. *Reprod Toxicol*. 2017;72:129–35.
  36. Allegaert K, van den Anker JN. Neonatal pain management: still in search for the holy grail. *Int J Clin Pharmacol Ther*. 2016;54(7):514–23.
  37. Rodieux F, Gotta V, Pfister M, van den Anker JN. Causes and consequences of variability in drug transporter activity in pediatric drug therapy. *J Clin Pharmacol*. 2016;56(Suppl 7):S173–92.
  38. Marsousi N, Desmeules JA, Rudaz S, Daali Y. Usefulness of PBPK modeling in incorporation of clinical conditions in personalized medicine. *J Pharm Sci*. 2017;106(9):2380–91.
  39. Chaccour C, Hammann F, Rabinovich NR. Ivermectin to reduce malaria transmission I. pharmacokinetic and pharmacodynamic considerations regarding efficacy and safety. *Malar J*. 2017;16(1):161.
  40. Viergever RF, Rademaker CM, Ghersi D. Pharmacokinetic research in children: an analysis of registered records of clinical trials. *BMJ Open*. 2011;1(1):e000221.
  41. Roth-Cline M, Nelson RM. Microdosing studies in children: a US regulatory perspective. *Clin Pharmacol Ther*. 2015;98(3):232–3.
  42. de Lange EC, Danhof M. Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain. *Clin Pharmacokinet*. 2002;41(10):691–703.
  43. Westerhout J, Smeets J, Danhof M, de Lange EC. The impact of P-gp functionality on non-steady state relationships between CSF and brain extracellular fluid. *J Pharmacokinet Pharmacodyn*. 2013;40(3):327–42.
  44. Yamamoto Y, Danhof M, de Lange ECM. Microdialysis: the key to physiologically based model prediction of human CNS target site concentrations. *AAPS J*. 2017;19(4):891–909.
  45. Yamamoto Y, Valitalo PA, van den Berg DJ, Hartman R, van den Brink W, Wong YC, *et al*. A generic multi-compartmental CNS distribution model structure for 9 drugs allows prediction of human brain target site concentrations. *Pharm Res*. 2017;34(2):333–51.
  46. Nikisch G, Baumann P, Oneda B, Kiessling B, Weisser H, Mathe AA, *et al*. Cytochrome P450 and ABCB1 genetics: association with quetiapine and norquetiapine plasma and cerebrospinal fluid concentrations and with clinical response in patients suffering from schizophrenia. A pilot study. *J Psychopharmacol*. 2011;25(7):896–907.
  47. Basic S, Hajnsek S, Bozina N, Filipic I, Sporis D, Mislov D, *et al*. The influence of C3435T polymorphism of ABCB1 gene on penetration of phenobarbital across the blood-brain barrier in patients with generalized epilepsy. *Seizure*. 2008;17(6):524–30.
  48. Rambeck B, Jurgens UH, May TW, Pannek HW, Behne F, Ebner A, *et al*. Comparison of brain extracellular fluid, brain

- tissue, cerebrospinal fluid, and serum concentrations of anti-epileptic drugs measured intraoperatively in patients with intractable epilepsy. *Epilepsia*. 2006;47(4):681–94.
49. Meineke I, Freudenthaler S, Hofmann U, Schaeffeler E, Mikus G, Schwab M, *et al*. Pharmacokinetic modelling of morphine, morphine-3-glucuronide and morphine-6-glucuronide in plasma and cerebrospinal fluid of neurosurgical patients after short-term infusion of morphine. *Br J Clin Pharmacol*. 2002;54(6):592–603.
  50. de Lannoy IA, Mandin RS, Silverman M. Renal secretion of vinblastine, vincristine and colchicine in vivo. *J Pharmacol Exp Ther*. 1994;268(1):388–95.
  51. Huang RS, Murry DJ, Foster DR. Role of xenobiotic efflux transporters in resistance to vincristine. *Biomed Pharmacother*. 2008;62(2):59–64.
  52. Xia CQ, Smith PG. Drug efflux transporters and multidrug resistance in acute leukemia: therapeutic impact and novel approaches to mediation. *Mol Pharmacol*. 2012;82(6):1008–21.
  53. Imrichova D, Cocolova M, Messingerova L, Sulova Z, Breier A. Vincristine-induced expression of P-glycoprotein in MOLM-13 and SKM-1 acute myeloid leukemia cell lines is associated with coexpression of nestin transcript. *Gen Physiol Biophys*. 2014;33(4):425–31.
  54. Huang R, Murry DJ, Kolwankar D, Hall SD, Foster DR. Vincristine transcriptional regulation of efflux drug transporters in carcinoma cell lines. *Biochem Pharmacol*. 2006;71(12):1695–704.
  55. Wang F, Zhou F, Kruh GD, Gallo JM. Influence of blood-brain barrier efflux pumps on the distribution of vincristine in brain and brain tumors. *Neuro-Oncology*. 2010;12(10):1043–9.
  56. Nicolai J, Thevelin L, Bing Q, Stieger B, Chanteux H, Augustijns P, *et al*. Role of the OATP transporter family and a Benzofuranone-Sensitive Efflux transporter in the hepatocellular disposition of vincristine. *Pharm Res*. 2017;34(11):2336–48.
  57. Wu JQ, Shao K, Wang X, Wang RY, Cao YH, Yu YQ, *et al*. In vitro and in vivo evidence for amphotericin B as a P-glycoprotein substrate on the blood-brain barrier. *Antimicrob Agents Chemother*. 2014;58(8):4464–9.
  58. Wurthwein G, Groll AH, Hempel G, Adler-Shohet FC, Lieberman JM, Walsh TJ. Population pharmacokinetics of amphotericin B lipid complex in neonates. *Antimicrob Agents Chemother*. 2005;49(12):5092–8.
  59. Hamill RJ, Sobel JD, El-Sadr W, Johnson PC, Graybill JR, Javaly K, *et al*. Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety. *Clin Infect Dis*. 2010;51(2):225–32.
  60. Vogelsinger H, Weiler S, Djanani A, Kountchev J, Bellmann-Weiler R, Wiedermann CJ, *et al*. Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion. *J Antimicrob Chemother*. 2006;57(6):1153–60.
  61. Strenger V, Meinitzer A, Donnerer J, Hofer N, Dornbusch HJ, Wanz U, *et al*. Amphotericin B transfer to CSF following intravenous administration of liposomal amphotericin B. *J Antimicrob Chemother*. 2014;69(9):2522–6.
  62. Hong Y, Shaw PJ, Tattam BN, Nath CE, Earl JW, Stephen KR, *et al*. Plasma protein distribution and its impact on pharmacokinetics of liposomal amphotericin B in paediatric patients with malignant diseases. *Eur J Clin Pharmacol*. 2007;63(2):165–72.
  63. Baley JE, Meyers C, Kliegman RM, Jacobs MR, Blumer JL. Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates. *J Pediatr*. 1990;116(5):791–7.
  64. Stevens DA, Clemons KV, Martinez M, Chen V. The brain, amphotericin B, and P-glycoprotein. *Antimicrob Agents Chemother*. 2015;59(2):1386.
  65. Osei-Twum JA, Wasan KM. Does P-glycoprotein contribute to amphotericin B epithelial transport in Caco-2 cells? *Drug Dev Ind Pharm*. 2015;41(7):1130–6.
  66. Sethi PK, White CA, Cummings BS, Hines RN, Muralidhara S, Bruckner JV. Ontogeny of plasma proteins, albumin and binding of diazepam, cyclosporine, and deltamethrin. *Pediatr Res*. 2016;79(3):409–15.
  67. Hargreaves RJ, Rabiner EA. Translational PET imaging research. *Neurobiol Dis*. 2014;61:32–8.
  68. Syvanen S, Eriksson J. Advances in PET imaging of P-glycoprotein function at the blood-brain barrier. *ACS Chem Neurosci*. 2013;4(2):225–37.
  69. Choo EF, Kurnik D, Muszkat M, Ohkubo T, Shay SD, Higginbotham JN, *et al*. Differential in vivo sensitivity to inhibition of P-glycoprotein located in lymphocytes, testes, and the blood-brain barrier. *J Pharmacol Exp Ther*. 2006;317(3):1012–8.
  70. Kurnik D, Sofowora GG, Donahue JP, Nair UB, Wilkinson GR, Wood AJ, *et al*. Tariquidar, a selective P-glycoprotein inhibitor, does not potentiate loperamide's opioid brain effects in humans despite full inhibition of lymphocyte P-glycoprotein. *Anesthesiology*. 2008;109(6):1092–9.
  71. Wagner CC, Bauer M, Karch R, Feurstein T, Kopp S, Chiba P, *et al*. A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET. *J Nucl Med*. 2009;50(12):1954–61.
  72. Bousquet L, Roucaïrol C, Hembury A, Nevers MC, Creminon C, Farinotti R, *et al*. Comparison of ABC transporter modulation by atazanavir in lymphocytes and human brain endothelial cells: ABC transporters are involved in the atazanavir-limited passage across an in vitro human model of the blood-brain barrier. *AIDS Res Hum Retrovir*. 2008;24(9):1147–54.
  73. Machado CG, Calado RT, Garcia AB, Falcao RP. Age-related changes of the multidrug resistance P-glycoprotein function in normal human peripheral blood T lymphocytes. *Braz J Med Biol Res*. 2003;36(12):1653–7.
  74. Giraud C, Declèves X, Perrot JY, Manceau S, Pannier E, Firtion G, *et al*. High levels of P-glycoprotein activity in human lymphocytes in the first 6 months of life. *Clin Pharmacol Ther*. 2009;85(3):289–95.
  75. Prasad B, Gaedigk A, Vrana M, Gaedigk R, Leeder JS, Salphati L, *et al*. Ontogeny of hepatic drug transporters as quantified by LC-MS/MS proteomics. *Clin Pharmacol Ther*. 2016;100(4):362–70.
  76. Johnson TN, Thomson M. Intestinal metabolism and transport of drugs in children: the effects of age and disease. *J Pediatr Gastroenterol Nutr*. 2008;47(1):3–10.
  77. Fakhoury M, Litalien C, Medard Y, Cave H, Ezzahir N, Peuchmaur M, *et al*. Localization and mRNA expression of CYP3A and P-glycoprotein in human duodenum as a function of age. *Drug Metab Dispos*. 2005;33(11):1603–7.
  78. Sun M, Kingdom J, Baczyk D, Lye SJ, Matthews SG, Gibb W. Expression of the multidrug resistance P-glycoprotein, (ABCB1 glycoprotein) in the human placenta decreases with advancing gestation. *Placenta*. 2006;27(6–7):602–9.
  79. Vandebossche J, Huisman M, Xu Y, Sanderson-Bongiovanni D, Soons P. Loperamide and P-glycoprotein inhibition: assessment of the clinical relevance. *J Pharm Pharmacol*. 2010;62(4):401–12.
  80. Chanzy S, Moretti S, Mayet H, Routon MC, De Gennes C, Mselati JC. Loss of consciousness in a child due to loperamide. *Arch Pediatr*. 2004;11(7):826–7.
  81. Motala C, Hill ID, Mann MD, Bowie MD. Effect of loperamide on stool output and duration of acute infectious diarrhea in infants. *J Pediatr*. 1990;117(3):467–71.
  82. Minton NA, Smith PG. Loperamide toxicity in a child after a single dose. *Br Med J (Clin Res Ed)*. 1987;294(6584):1383.
  83. Megarbane B, Alhaddad H. P-glycoprotein should be considered as an additional factor contributing to opioid-induced respiratory depression in paediatrics: the buprenorphine example. *Br J Anaesth*. 2013;110(5):842.
  84. Kraft WK. Buprenorphine in neonatal abstinence syndrome. *Clin Pharmacol Ther*. 2018;103(1):112–9.
  85. Liao MZ, Gao C, Shireman LM, Phillips B, Risler LJ, Neradugomma NK, *et al*. P-gp/ABCB1 exerts differential impacts on brain and fetal exposure to norbuprenorphine. *Pharmacol Res*. 2017;119:61–71.

86. Kim HK, Smiddy M, Hoffman RS, Nelson LS. Buprenorphine may not be as safe as you think: a pediatric fatality from unintentional exposure. *Pediatrics*. 2012;130(6):e1700–3.
87. Toce MS, Burns MM, O'Donnell KA. Clinical effects of unintentional pediatric buprenorphine exposures: experience at a single tertiary care center. *Clin Toxicol (Phila)*. 2017;55(1):12–7.
88. Hayes BD, Klein-Schwartz W, Doyon S. Toxicity of buprenorphine overdoses in children. *Pediatrics*. 2008;121(4):e782–6.
89. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P. Absence of the mdrla P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin a. *J Clin Invest*. 1995;96(4):1698–705.
90. Brophy GM, Mazzeo AT, Brar S, Alves OL, Bunnell K, Gilman C, *et al*. Exposure of cyclosporin a in whole blood, cerebral spinal fluid, and brain extracellular fluid dialysate in adults with traumatic brain injury. *J Neurotrauma*. 2013;30(17):1484–9.
91. Taque S, Peudenier S, Gie S, Rambeau M, Gandemer V, Bridoux L, *et al*. Central neurotoxicity of cyclosporine in two children with nephrotic syndrome. *Pediatr Nephrol*. 2004;19(3):276–80.
92. Menache CC, du Plessis AJ, Wessel DL, Jonas RA, Newburger JW. Current incidence of acute neurologic complications after open-heart operations in children. *Ann Thorac Surg*. 2002;73(6):1752–8.
93. Wijdicks EF. Neurotoxicity of immunosuppressive drugs. *Liver Transpl*. 2001;7(11):937–42.
94. Yanagimachi M, Naruto T, Tanoshima R, Kato H, Yokosuka T, Kajiwara R, *et al*. Influence of CYP3A5 and ABCB1 gene polymorphisms on calcineurin inhibitor-related neurotoxicity after hematopoietic stem cell transplantation. *Clin Transpl*. 2010;24(6):855–61.
95. Reddy GK, Brown B, Nanda A. Fatal consequences of a simple mistake: how can a patient be saved from inadvertent intrathecal vincristine? *Clin Neurol Neurosurg*. 2011;113(1):68–71.
96. Jackson DV Jr, Sethi VS, Spurr CL, McWhorter JM. Pharmacokinetics of vincristine in the cerebrospinal fluid of humans. *Cancer Res*. 1981;41(4):1466–8.
97. Tomiwa K, Hazama F, Mikawa H. Neurotoxicity of vincristine after the osmotic opening of the blood-brain barrier. *Neuropathol Appl Neurobiol*. 1983;9(5):345–54.
98. Krugman L, Bryan JN, Mealey KL, Chen A. Vincristine-induced central neurotoxicity in a collie homozygous for the ABCB1Delta mutation. *J Small Anim Pract*. 2012;53(3):185–7.
99. Eiden C, Palenzuela G, Hillaire-Buys D, Margueritte G, Cociglio M, Hansel-Esteller S, *et al*. Posaconazole-increased vincristine neurotoxicity in a child: a case report. *J Pediatr Hematol Oncol*. 2009;31(4):292–5.
100. Rothmond DA, Weickert CS, Webster MJ. Developmental changes in human dopamine neurotransmission: cortical receptors and terminators. *BMC Neurosci*. 2012;13:18.
101. Chugani DC, Muzik O, Juhasz C, Janisse JJ, Ager J, Chugani HT. Postnatal maturation of human GABAA receptors measured with positron emission tomography. *Ann Neurol*. 2001;49(5):618–26.
102. Chugani HT, Kumar A, Muzik O. GABA(a) receptor imaging with positron emission tomography in the human newborn: a unique binding pattern. *Pediatr Neurol*. 2013;48(6):459–62.
103. Talos DM, Chang M, Kosaras B, Fitzgerald E, Murphy A, Folkerth RD, *et al*. Antiepileptic effects of levetiracetam in a rodent neonatal seizure model. *Pediatr Res*. 2013;73(1):24–30.
104. Saunders NR, Dziegielewska KM, Mollgard K, Habgood MD. Recent developments in understanding barrier mechanisms in the developing brain: drugs and drug transporters in pregnancy, susceptibility or protection in the fetal brain? *Annu Rev Pharmacol Toxicol*. 2019;59:487–505.
105. Ek CJ, Dziegielewska KM, Habgood MD, Saunders NR. Barriers in the developing brain and Neurotoxicology. *Neurotoxicology*. 2012;33(3):586–604.
106. Hoffmann P, Beckman D, McLean LA, Yan JH. Aliskiren toxicity in juvenile rats is determined by ontogenic regulation of intestinal P-glycoprotein expression. *Toxicol Appl Pharmacol*. 2014;275(1):36–43.
107. Ek CJ, Wong A, Liddelow SA, Johansson PA, Dziegielewska KM, Saunders NR. Efflux mechanisms at the developing brain barriers: ABC-transporters in the fetal and postnatal rat. *Toxicol Lett*. 2010;197(1):51–9.
108. Matsuoka Y, Okazaki M, Kitamura Y, Taniguchi T. Developmental expression of P-glycoprotein (multidrug resistance gene product) in the rat brain. *J Neurobiol*. 1999;39(3):383–92.
109. Morimoto K, Nagami T, Matsumoto N, Wada S, Kano T, Kakinuma C, *et al*. Developmental changes of brain distribution and localization of oseltamivir and its active metabolite Ro 64-0802 in rats. *J Toxicol Sci*. 2012;37(6):1217–23.
110. Gazzin S, Strazielle N, Schmitt C, Fevre-Montange M, Ostrow JD, Tiribelli C, *et al*. Differential expression of the multidrug resistance-related proteins ABCB1 and ABCG1 between blood-brain interfaces. *J Comp Neurol*. 2008;510(5):497–507.
111. Goralski KB, Acott PD, Fraser AD, Worth D, Sinal CJ. Brain cyclosporin a levels are determined by ontogenic regulation of mdrla expression. *Drug Metab Dispos*. 2006;34(2):288–95.
112. Tsai CE, Daood MJ, Lane RH, Hansen TW, Gruetzmacher EM, Watchko JF. P-glycoprotein expression in mouse brain increases with maturation. *Biol Neonate*. 2002;81(1):58–64.
113. Buelke-Sam J, editor. Comparative schedules of development in rats and humans: Implications for developmental neurotoxicity testing. Abstract 820 presented at the Society of Toxicology Annual Meeting, Salt Lake City, UT, USA, 9–13 March, 2003.
114. Nicolas JM, Bouzom F, Hugues C, Ungell AL. Oral drug absorption in pediatrics: the intestinal wall, its developmental changes and current tools for predictions. *Biopharm Drug Dispos*. 2016.
115. Johnson TN, Tanner MS, Taylor CJ, Tucker GT. Enterocytic CYP3A4 in a paediatric population: developmental changes and the effect of coeliac disease and cystic fibrosis. *Br J Clin Pharmacol*. 2001;51(5):451–60.
116. Stenling R, Fredrikzon B, Nyhlin H, Helander HF, Falkmer S. Surface ultrastructure of the small intestine mucosa in healthy children and adults: a scanning electron microscopic study with some methodological aspects. *Ultrastruct Pathol*. 1984;6(2–3):131–40.
117. Cornes JS. Number, size, and distribution of Peyer's patches in the human small intestine: part II the effect of age on Peyer's patches. *Gut*. 1965;6(3):230–3.
118. Syvanen S, Lindhe O, Palner M, Kornum BR, Rahman O, Langstrom B, *et al*. Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport. *Drug Metab Dispos*. 2009;37(3):635–43.
119. Uchida Y, Wakayama K, Ohtsuki S, Chiba M, Ohe T, Ishii Y, *et al*. Blood-brain barrier pharmacoproteomics-based reconstruction of the in vivo brain distribution of P-glycoprotein substrates in cynomolgus monkeys. *J Pharmacol Exp Ther*. 2014;350(3):578–88.
120. Hoshi Y, Uchida Y, Tachikawa M, Inoue T, Ohtsuki S, Terasaki T. Quantitative atlas of blood-brain barrier transporters, receptors, and tight junction proteins in rats and common marmoset. *J Pharm Sci*. 2013;102(9):3343–55.
121. Maharaj AR, Edginton AN. Physiologically based pharmacokinetic modeling and simulation in pediatric drug development. *CPT Pharmacometrics Syst Pharmacol*. 2014;3(11):1–13.
122. Leong R, Vieira ML, Zhao P, Mulugeta Y, Lee CS, Huang SM, *et al*. Regulatory experience with physiologically based pharmacokinetic modeling for pediatric drug trials. *Clin Pharmacol Ther*. 2012;91(5):926–31.
123. Rioux N, Waters NJ. Physiologically based pharmacokinetic modeling in pediatric oncology drug development. *Drug Metab Dispos*. 2016;44(7):934–43.
124. Maharaj AR, Barrett JS, Edginton AN. A workflow example of PBPK modeling to support pediatric research and development: case study with lorazepam. *AAPS J*. 2013;15(2):455–64.
125. Johnson TN, Rostami-Hodjegan A, Tucker GT. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. *Clin Pharmacokinet*. 2006;45(9):931–56.

126. Zhou W, Johnson TN, Xu H, Cheung S, Bui KH, Li J, *et al.* Predictive performance of physiologically based pharmacokinetic and population pharmacokinetic modeling of Renally cleared drugs in children. *CPT Pharmacometrics Syst Pharmacol.* 2016;5(9):475–83.
127. Edginton AN, Schmitt W, Willmann S. Development and evaluation of a generic physiologically based pharmacokinetic model for children. *Clin Pharmacokinet.* 2006;45(10):1013–34.
128. Bjorkman S. Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. *Br J Clin Pharmacol.* 2005;59(6):691–704.
129. Ogungbenro K, Aarons L, Cresim ECPG. A physiologically based pharmacokinetic model for Valproic acid in adults and children. *Eur J Pharm Sci.* 2014;63:45–52.
130. Hornik CP, Wu H, Edginton AN, Watt K, Cohen-Wolkowicz M, Gonzalez D. Development of a pediatric physiologically-based pharmacokinetic model of clindamycin using opportunistic pharmacokinetic data. *Clin Pharmacokinet.* 2017;56(11):1343–53.
131. Willmann S, Becker C, Burghaus R, Coboeken K, Edginton A, Lippert J, *et al.* Development of a paediatric population-based model of the pharmacokinetics of rivaroxaban. *Clin Pharmacokinet.* 2014;53(1):89–102.
132. Thai HT, Mazuir F, Cartot-Cotton S, Veyrat-Follet C. Optimizing pharmacokinetic bridging studies in paediatric oncology using physiologically-based pharmacokinetic modelling: application to docetaxel. *Br J Clin Pharmacol.* 2015;80(3):534–47.
133. Abdel-Rahman SM, Amidon GL, Kaul A, Lukacova V, Vinks AA, Knipp GT, *et al.* Summary of the National Institute of Child Health and Human Development-best pharmaceuticals for children act pediatric formulation initiatives workshop-pediatric biopharmaceutics classification system working group. *Clin Ther.* 2012;34(11):S11–24.
134. Fenneteau F, Li J, Nekka F. Assessing drug distribution in tissues expressing P-glycoprotein using physiologically based pharmacokinetic modeling: identification of important model parameters through global sensitivity analysis. *J Pharmacokinet Pharmacodyn.* 2009;36(6):495–522.
135. Fenneteau F, Turgeon J, Couture L, Michaud V, Li J, Nekka F. Assessing drug distribution in tissues expressing P-glycoprotein through physiologically based pharmacokinetic modeling: model structure and parameters determination. *Theor Biol Med Model.* 2009;6:2. <https://doi.org/10.1186/742-4682-6-2>.
136. Ball K, Bouzom F, Scherrmann JM, Walther B, Decleves X. Physiologically based pharmacokinetic modelling of drug penetration across the blood-brain barrier—towards a mechanistic IVIVE-based approach. *AAPS J.* 2013;15(4):913–32.
137. Sjostedt N, Kortejarvi H, Kidron H, Vellonen KS, Urtti A, Yliperttula M. Challenges of using in vitro data for modeling P-glycoprotein efflux in the blood-brain barrier. *Pharm Res.* 2014;31(1):1–19.
138. Yamamoto Y, Valitalo PA, Huntjens DR, Proost JH, Vermeulen A, Krauwinkel W, *et al.* Predicting drug concentration-time profiles in multiple CNS compartments using a comprehensive physiologically-based pharmacokinetic model. *CPT Pharmacometrics Syst Pharmacol.* 2017.
139. Yamamoto Y, Valitalo PA, Wong YC, Huntjens DR, Proost JH, Vermeulen A, *et al.* Prediction of human CNS pharmacokinetics using a physiologically-based pharmacokinetic modeling approach. *Eur J Pharm Sci.* 2017;112:168–79.
140. Ketharanathan N, Yamamoto Y, Rohlwick UK, Wildschut ED, Mathot RAA, de Lange ECM, *et al.* Combining brain microdialysis and translational pharmacokinetic modeling to predict drug concentrations in pediatric severe traumatic brain injury: the next step toward evidence-based pharmacotherapy? *J Neurotrauma.* 2019;36(1):111–7.
141. Baello S, Iqbal M, Gibb W, Matthews SG. Astrocyte-mediated regulation of multidrug resistance p-glycoprotein in fetal and neonatal brain endothelial cells: age-dependent effects. *Physiol Rep.* 2016;4(16):e12853.
142. Alvarez JI, Katayama T, Prat A. Glial influence on the blood brain barrier. *Glia.* 2013;61(12):1939–58.
143. Baello S, Iqbal M, Bloise E, Javam M, Gibb W, Matthews SG. TGF-beta1 regulation of multidrug resistance P-glycoprotein in the developing male blood-brain barrier. *Endocrinology.* 2014;155(2):475–84.

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.